Research
Hormonal
SGLT-2 inhibitors slow the progression of chronic kidney disease (CKD) and reduce the risk of end-stage kidney disease (ESKD) in patients with type 2 diabetes and albuminuria.
If you have diabetes and early kidney disease (albuminuria), SGLT-2 inhibitors (like Jardiance or Invokana) are recommended to protect your kidneys. They slow down the decline of kidney function and reduce the risk of needing dialysis, even if your blood sugar is already controlled.
StrongSupportsVERY_HIGH confidence
The relative risk of the renal-specific composite of ESKD, serum creatinine doubling, or renal death was 34% lower in the canagliflozin group (HR 0.66; P<0.001).
Why this rating
Based on CREDENCE and DAPA-CKD trials stopped early for efficacy.
Source
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner · The Journal of Family Practice · 2021
DOI 10.12788/jfp.0221
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular death and heart failure hospitalizations in patients with type 2 diabetes, heart failure, or chronic kidney disease, regardless of baseline glycemic control.Strong
- SGLT-2 inhibitors reduce the risk of worsening heart failure and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →